Glucocorticoid-induced osteoporosis: Whats new? | 2159
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+44 1478 350008

Glucocorticoid-induced osteoporosis: Whats new?

4th International Conference on Clinical & Experimental Dermatology

April 14-16, 2014 Hilton San Antonio Airport, TX, USA

Farrokh Khosravi and Reza F Ghohestani

Scientific Tracks Abstracts: J Clin Exp Dermatol Res

Abstract :

Glucocorticoid-induced osteoporosis (GIO) is one of the most challenging health issue in the aged population. Up to fifty percent of chronic glucocorticoid-treated patients will experience at least one osteoporosis related fracture. Any attempt to prevent GIO will significantly decrease patients� morbidity and mortality. Novel drugs have been recently developed for preventing and/or treating GIO. New methods of detection, prevention and treatment of GIO will be discussed in this talk.

Biography :

Farrokh Khosravi has completed his fellowship of Rheumatology at the age of 38 years from Shiraz University. He is a part time Assistant Professor of Medicine. His field of interest is autoimmune skin disease and has published papers in field of Behcet?s disease and Multicentric Reticulohistiocytosis in reputed journals and served as an reviewer for Journal of Hormozgan University of Medical Sciences.